Neuropathic Pain Pipeline Insight 2021: Pre-Clinical and Discovery Stage Candidates, Phase III, Phase II and Phase I, Discontinued and Inactive Candidates – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Neuropathic Pain – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Neuropathic Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The companies and academics are working to assess challenges and seek opportunities that could influence Neuropathic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Neuropathic Pain .

Neuropathic Pain Emerging Drugs Chapters: This segment of the Neuropathic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neuropathic Pain : Therapeutic Assessment: This segment of the report provides insights about the different Neuropathic Pain drugs segregated based on following parameters that define the scope of the report, such as:

This report covers around 80+ products under different phases of clinical development including:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neuropathic Pain therapeutic drugs key players involved in developing key drugs.

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neuropathic Pain drugs.

Key Questions Answered

• How many companies are developing Neuropathic Pain drugs?
• How many Neuropathic Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neuropathic Pain ?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Neuropathic Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neuropathic Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Yuhan
• Algiax Pharmaceuticals
• Haisco Pharmaceutical Group Co., Ltd.
• Xalud Therapeutics, Inc.
• Bayer
• Novaremed Ltd.
• Eli Lilly and Company
• Aptinyx
• Toray Industries, Inc
• Allergan
• Lateral Pharma
• Eliem Therapeutics (UK) Ltd.
• SR419
• Biogen
• Lexicon Pharmaceuticals
• Flexion Therapeutics
• Neurofix S.L.
• Relmada Therapeutics, Inc.
• AlgoTherapeutix
• Abide Therapeutics
• SK biopharmaceuticals
• Kineta
• Shionogi
• Tools4Patient
• Newron Pharmaceuticals
• Fortovia Therapeutics
• Saniona
• Esteve
• OKYO Pharma

Key Topics Covered:

• Neuropathic Pain : Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Neuropathic Pain – Analytical Perspective
• Late Stage Products (Phase III)
• YHD 1119: Yuhan
• Mid Stage Products (Phase II)
• AP-325: Algiax Pharmaceuticals
• Early Stage Products (Phase I)
• SR419: SIMR Biotech
• Preclinical and Discovery Stage Products
• OK 101: OKYO Pharma
• Inactive Products
• Neuropathic Pain Key Companies
• Neuropathic Pain Key Products
• Neuropathic Pain: Unmet Needs
• Neuropathic Pain: Market Drivers and Barriers
• Neuropathic Pain: Future Perspectives and Conclusion
• Neuropathic Pain: Analyst Views
• Neuropathic Pain: Key Companies

   

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/2tzfik

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900